Metabolic Dysfunction-associated Steatotic Liver Disease
The central purpose of the Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) SIG (formerly the NAFLD SIG) is to provide a forum to share ideas, foster collaboration and brainstorm together as an academy of basic and translational investigators. Our mission is to study the pathogenesis, diagnosis, natural history and development of therapeutics for metabolic dysfunction-associated steatotic Liver disease. The MASLD SIG sponsors programs at the AASLD Annual Meeting, identifies emerging topics in MASLD, and supports the educational mission of AASLD policy.
SIG Leadership
Chair
Alina M. Allen, MD
Vice Chair
Amreen Dinani, MD, FRCPC
Associate Lead
Jessica Bartholomew, NP
Communication Lead
Pinelopi Manousou, MD, PhD, FRCP
Education Lead
Robert J. Fontana, MD, FAASLD
Trainee Lead
Maria Mironova, MD, MHSc
ELAPP Ex-Officio
Sonnet Aguirre, PA, MS, RDN
ADVHep Ex-Officio
Christine Brichta, MD, MPH
Staff Liaisons
Akuender Dot, MPH
Julie Hoffman, MBA